The human Dihydroorotate Dehydrogenase (hDHODH) plays a pivotal role in de novo pyrimidine biosynthesis, controlling vital cellular functions and survival. Recently, hDHODH, a validated target for treatment of autoimmune diseases has related to acute myeloid leukaemia (AML), being hDHODH inhibitor able to restore the myeloid differentiation. We developed a new class of hDHODH inhibitors [1], being M433 (IC50 = 1.2 nM) the most interesting. In this occasion, we profiled these compounds for their physicochemical properties as drugs, i.e. lipophilicity, solubility, biological fluids stability, protein binding and in vitro metabolism. Compound M433 was also studied in vivo, in order to determinate its pharmacokinetic profile. We quantified plasma concentration of M433 by LC-MS/MS in MRM mode in female and male CD-1 mice, after a single intravenous dose (5 mg/Kg). Moreover, in vivo toxicity was evaluated in Balb mice, treated the animals for 35 days with two different doses of M433 (10 and 25 mg/Kg), all mice tissues were evaluated and compared to controls. Drug-like properties, pharmacokinetic and toxicity profile are presented and discussed. The data obtained will be useful for planning the design of the next generation of inhibitors, while future tests to determine the complete ADME-Tox profile.

Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML)

Giulia De Simone;Stefano Sainas;Marilena Marraudino;Agnese Chiara Pippione;Brigitta Bonaldo;Marta Giorgis;Barbara Rolando;Donatella Boschi;Marco Lucio Lolli
2019

Abstract

The human Dihydroorotate Dehydrogenase (hDHODH) plays a pivotal role in de novo pyrimidine biosynthesis, controlling vital cellular functions and survival. Recently, hDHODH, a validated target for treatment of autoimmune diseases has related to acute myeloid leukaemia (AML), being hDHODH inhibitor able to restore the myeloid differentiation. We developed a new class of hDHODH inhibitors [1], being M433 (IC50 = 1.2 nM) the most interesting. In this occasion, we profiled these compounds for their physicochemical properties as drugs, i.e. lipophilicity, solubility, biological fluids stability, protein binding and in vitro metabolism. Compound M433 was also studied in vivo, in order to determinate its pharmacokinetic profile. We quantified plasma concentration of M433 by LC-MS/MS in MRM mode in female and male CD-1 mice, after a single intravenous dose (5 mg/Kg). Moreover, in vivo toxicity was evaluated in Balb mice, treated the animals for 35 days with two different doses of M433 (10 and 25 mg/Kg), all mice tissues were evaluated and compared to controls. Drug-like properties, pharmacokinetic and toxicity profile are presented and discussed. The data obtained will be useful for planning the design of the next generation of inhibitors, while future tests to determine the complete ADME-Tox profile.
19th edition of the Merck Young Chemists' Symposium (MYCS-2019)
Rimini
25 - 27 Novembre, 2019.
Merck Young Chemist Symposium 2019 (MYCS-2019)
149
149
Giulia De Simone, Stefano Sainas, Marilena Marraudino, Agnese Chiara Pippione, Brigitta Bonaldo, Alice Passoni, Marta Giorgis, Barbara Rolando, Donatella Boschi, Marco Lucio Lolli
File in questo prodotto:
File Dimensione Formato  
Book of abstracts 2019.pdf

non disponibili

Descrizione: Book of Abstract
Tipo di file: PDF EDITORIALE
Dimensione 10.39 MB
Formato Adobe PDF
10.39 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1852024
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact